Castleark Management’s Amgen AMGN Stock Holding History

Castleark Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,000	Closed	-$292K	–	372
2016 Q4	$292K	Hold	2,000	–	–	0.01%	332
2016 Q3	$334K	Hold	2,000	–	–	0.01%	317
2016 Q2	$304K	Hold	2,000	–	–	0.01%	314
2016 Q1	$300K	Hold	2,000	–	–	0.01%	315
2015 Q4	$325K	Hold	2,000	–	–	0.01%	325
2015 Q3	$277K	Hold	2,000	–	–	0.01%	327
2015 Q2	$307K	Hold	2,000	–	–	0.01%	338
2015 Q1	$320K	Hold	2,000	–	–	0.01%	329
2014 Q4	$319K	Hold	2,000	–	–	0.01%	304
2014 Q3	$247K	Hold	2,000	–	–	0.01%	288
2014 Q2	$237K	Hold	2,000	–	–	0.01%	299
2014 Q1	$247K	Hold	2,000	–	–	0.01%	288
2013 Q4	$228K	Sell	2,000 -465,612	-100%	-$53M	0.01%	299
2013 Q3	$65.7M	Buy	467,612 +465,612	+23,281%	+$50.5M	1.85%	9
2013 Q2	$197K	Buy	+2,000	New	+$208K	0.01%	284

Other funds holding AMGN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Castleark Management's AMGN Position: Q1 2017 in Review

Castleark Management sold out of Amgen (AMGN) in Q1 2017, closing a stake of 2,000 shares — an estimated $292K sold.

Castleark Management first reported a position in AMGN in Q2 2013 and held it in 15 quarters. The position peaked at $65.7M in Q3 2013. 1,600 funds tracked by Wall St. Rank hold AMGN as of Q1 2017.

Castleark Management reported no remaining Amgen position as of Q1 2017 after selling out during the quarter.
Castleark Management sold 2,000 Amgen shares in Q1 2017, an estimated $292K.
Castleark Management first reported a position in Amgen in Q2 2013 and held it in 15 quarters.
Castleark Management's Amgen position peaked at $65.7M in Q3 2013.
1,600 funds tracked by Wall St. Rank held Amgen as of Q1 2017.

Based on Castleark Management's 13F filing for Q1 2017, filed 15 May 2017.